Q3 2024 2Seventy Bio Inc Earnings Call Transcript
Key Points
- 2seventy bio Inc (TSVT) successfully completed the sale of its oncology and autoimmune R&D pipeline to Regeneron, streamlining operations.
- The company received FDA approval for Abecma in the third-line setting, expanding its availability to more multiple myeloma patients.
- Third quarter US revenues for Abecma grew by 42% over the previous quarter, indicating strong market performance.
- 2seventy bio Inc (TSVT) achieved a significant reduction in its burn rate, down to approximately $10 million this quarter.
- The company has made substantial progress towards breakeven operations, with expectations to potentially achieve this by 2025.
- The multiple myeloma market remains highly competitive, impacting Abecma's market share.
- Fourth quarter revenues are expected to be affected by competition and a reduction in CAR T infusion schedules during the US holiday season.
- Despite improvements, the company still faces challenges in optimizing the cost structure to increase operating margins.
- Enrollment in the Carmen nine study was discontinued as part of financial discipline measures.
- The company is still less than 25% penetrated into the overall third-line setting, indicating room for growth but also highlighting current limitations.
Good day. And thank you for standing by. Welcome to the 2 seventyBio third quarter, 2024 earnings conference call. At this time. All participants are in listen-only mode after the speaker's presentation, there will be a question and answer session to ask a question during the session. You will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised to withdraw your question. Please press star 11 again. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Morgan Shields in corporate communications. Please go ahead.
Thank you, operator. Good morning, everyone. And thank you for joining us this morning. We issued a press release on our third quarter, 2024 financial results. The press release can be found in the investors and media section of the company's website at 2 seventybio.com. As a reminder, today's discussion will include forward-looking statements related
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
